Intestinal tumorigenesis is not affected by progesterone signaling in rodent models

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Heijmans, Jarom ^a,b   Muncan, Vanesa ^a,b   Jacobs, Rutger J ^a   de Jonge Muller, Eveline S M ^a   Graven, Laura ^a   Biemond, Izak ^a   Ederveen, Antwan G ^c   Groothuis, Patrick G ^c   Mosselman, Sietse ^c   Hardwick, James C ^a   Hommes, Daniel W ^a   van den Brink, Gijs R ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c NV ORGANON   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MEDROXYPROGESTERONE ACETATE; PLACEBO; PROGESTERONE; PROGESTERONE RECEPTOR; GESTAGEN;

ABERRANT CRYPT FOCUS; ADENOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; CANCER LOCALIZATION; CARCINOGENESIS; CELL PROLIFERATION; COLORECTAL CARCINOMA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; FEMALE; GASTROINTESTINAL POLYPOSIS; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; INTESTINE CANCER; INTESTINE EPITHELIUM; MALE; MESENCHYME CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RODENT; SIGNAL TRANSDUCTION; TUMOR VOLUME; ANIMAL; CELL TRANSFORMATION; COLON; DISEASE MODEL; INTESTINE MUCOSA; INTESTINE TUMOR; METABOLISM; PATHOLOGY; SMALL INTESTINE;

MUS; RATTUS; RODENTIA;

ANIMALS; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COLON; DISEASE MODELS, ANIMAL; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; INTESTINAL NEOPLASMS; INTESTINAL POLYPOSIS; INTESTINE, SMALL; MICE; PROGESTERONE; PROGESTINS; RATS; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION;

EID: 79960758579     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022620     Document Type: Article

References (39)

1. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291: 1701-1712.
2. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288: 321-333.
3. Ritenbaugh C, Stanford JL, Wu L, Shikany JM, Schoen RE, et al. (2008) Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev 17: 2609-2618.
4. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, et al. (2004) Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 350: 991-1004.
5. Half E, Arber N, (2009) Colon cancer: preventive agents and the present status of chemoprevention. Expert Opin Pharmacother 10: 211-219.
6. Giardiello FM, Hylind LM, Trimbath JD, Hamilton SR, Romans KE, et al. (2005) Oral contraceptives and polyp regression in familial adenomatous polyposis. Gastroenterology 128: 1077-1080.
7. Martin L, Finn CA, Trinder G, (1973) DNA synthesis in the endometrium of progesterone-treated mice. J Endocrinol 56: 303-307.
8. Asselin-Labat ML, Vaillant F, Sheridan JM, Pal B, Wu D, et al. (2010) Control of mammary stem cell function by steroid hormone signalling. Nature 465: 798-802.
9. Rickard DJ, Iwaniec UT, Evans G, Hefferan TE, Hunter JC, et al. (2008) Bone growth and turnover in progesterone receptor knockout mice. Endocrinology 149: 2383-2390.
10. Mani SK, Reyna AM, Chen JZ, Mulac-Jericevic B, Conneely OM, (2006) Differential response of progesterone receptor isoforms in hormone-dependent and-independent facilitation of female sexual receptivity. Mol Endocrinol 20: 1322-1332.
11. Blois SM, Ilarregui JM, Tometten M, Garcia M, Orsal AS, et al. (2007) A pivotal role for galectin-1 in fetomaternal tolerance. Nat Med 13: 1450-1457.
12. Hughes GC, Thomas S, Li C, Kaja MK, Clark EA, (2008) Cutting edge: progesterone regulates IFN-alpha production by plasmacytoid dendritic cells. J Immunol 180: 2029-2033.
13. Jones LA, Kreem S, Shweash M, Paul A, Alexander J, et al. (2010) Differential modulation of. J Immunol 185: 4525-4534.
14. Mote PA, rnett-Mansfield RL, Gava N, deFazio A, Mulac-Jericevic B, et al. (2006) Overlapping and distinct expression of progesterone receptors A and B in mouse uterus and mammary gland during the estrous cycle. Endocrinology 147: 5503-5512.
15. Ismail PM, Amato P, Soyal SM, DeMayo FJ, Conneely OM, et al. (2003) Progesterone involvement in breast development and tumorigenesis-as revealed by progesterone receptor "knockout" and "knockin" mouse models. Steroids 68: 779-787 S0039128X03001338 [pii].
16. Singh S, Sheppard MC, Langman MJ, (1993) Sex differences in the incidence of colorectal cancer: an exploration of oestrogen and progesterone receptors. Gut 34: 611-615.
17. Sica V, Nola E, Contieri E, Bova R, Masucci MT, et al. (1984) Estradiol and progesterone receptors in malignant gastrointestinal tumors. Cancer Res 44: 4670-4674.
18. Meggouh F, Lointier P, Pezet D, Saez S, (1991) Status of sex steroid hormone receptors in large bowel cancer. Cancer 67: 1964-1970.
19. Slattery ML, Samowitz WS, Holden JA, (2000) Estrogen and progesterone receptors in colon tumors. Am J Clin Pathol 113: 364-368.
20. Tanaka Y, Kato K, Mibu R, Uchida S, Asanoma K, et al. (2008) Medroxyprogesterone acetate inhibits proliferation of colon cancer cell lines by modulating cell cycle-related protein expression. Menopause 15: 442-453.
21. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, et al. (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118: 285-296 10.1016/j.cell.2004.07.013 [doi];S0092867404006713 [pii].
22. Hardwick JC, van den Brink GR, Offerhaus GJ, van Deventer SJ, Peppelenbosch MP, (2001) NF-kappaB, p38 MAPK and JNK are highly expressed and active in the stroma of human colonic adenomatous polyps. Oncogene 20: 819-827 10.1038/sj.onc.1204162 [doi].
23. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, et al. (2004) TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21: 491-501 S1074761304002432 [pii];10.1016/j.immuni.2004.07.020 [doi].
24. Taketo MM, Edelmann W, (2009) Mouse models of colon cancer. Gastroenterology 136: 780-798.
25. McCart AE, Vickaryous NK, Silver A, (2008) Apc mice: models, modifiers and mutants. Pathol Res Pract 204: 479-490 S0344-0338(08)00073-3 [pii];10.1016/j.prp.2008.03.004 [doi].
26. Beazer-Barclay Y, Levy DB, Moser AR, Dove WF, Hamilton SR, et al. (1996) Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis 17: 1757-1760.
27. Bentel JM, Birrell SN, Pickering MA, Holds DJ, Horsfall DJ, et al. (1999) Androgen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cells. Mol Cell Endocrinol 154: 11-20.
28. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS, (1986) Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci U S A 83: 2496-2500.
29. Kirton KT, Cornette JC, (1974) Return of ovulatory cyclicity following an intramuscular injection of medroxyprogesterone acetate (Provera). Contraception 10: 39-45.
30. Cao L, Liu X, Lin EJ, Wang C, Choi EY, et al. (2010) Environmental and genetic activation of a brain-adipocyte BDNF/leptin axis causes cancer remission and inhibition. Cell 142: 52-64.
31. Neufert C, Becker C, Neurath MF, (2007) An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc 2: 1998-2004.
32. Bird RP, (1987) Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 37: 147-151.
33. Takayama T, Katsuki S, Takahashi Y, Ohi M, Nojiri S, et al. (1998) Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 339: 1277-1284.
34. Moser AR, Pitot HC, Dove WF, (1990) A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247: 322-324.
35. Mulac-Jericevic B, Lydon JP, DeMayo FJ, Conneely OM, (2003) Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform. Proc Natl Acad Sci U S A 100: 9744-9749 10.1073/pnas.1732707100 [doi];1732707100 [pii].
36. Zhang Z, Olland AM, Zhu Y, Cohen J, Berrodin T, et al. (2005) Molecular and pharmacological properties of a potent and selective novel nonsteroidal progesterone receptor agonist tanaproget. J Biol Chem 280: 28468-28475 M504144200 [pii];10.1074/jbc.M504144200 [doi].
37. Reagan-Shaw S, Nihal M, Ahmad N, (2008) Dose translation from animal to human studies revisited. FASEB J 22: 659-661 fj.07-9574LSF [pii];10.1096/fj.07-9574LSF [doi].
38. Yamanouchi K, Soeta C, Naito K, Tojo H, (2000) Progesterone Pretreatment Inhibits the Expression of c-ski mRNA and Epithelial Cell Proliferation Induced by Estrogen in the Rat Uterus. j Reprod Dev 46: 257-263.
39. Wood GA, Fata JE, Watson KL, Khokha R, (2007) Circulating hormones and estrous stage predict cellular and stromal remodeling in murine uterus. Reproduction 133: 1035-1044.